Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

被引：0
|
作者：
Hisamitsu Ishihara
Susumu Yamaguchi
Ikko Nakao
Seitaro Asahina
Taishi Sakatani
机构：
[1] Nihon University School of Medicine,Division of Diabetes and Metabolic Diseases
[2] Astellas Pharma Inc.,undefined
来源：
Diabetology International | 2019年 / 10卷
关键词：
Dipeptidyl peptidase-4 inhibitor; Insulin; Ipragliflozin; Sodium–glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：37 / 50
页数：13
相关论文
共 50 条
  • [1] Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study
    Ishihara, Hisamitsu
    Yamaguchi, Susumu
    Nakao, Ikko
    Asahina, Seitaro
    Sakatani, Taishi
    DIABETOLOGY INTERNATIONAL, 2019, 10 (01) : 37 - 50
  • [2] Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension
    Kadowaki, Takashi
    Muto, Satsuki
    Ouchi, Yoshiumi
    Shimazaki, Ryutaro
    Seino, Yutaka
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (18) : 1903 - 1919
  • [3] Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period
    Kadowaki, Takashi
    Kondo, Kazuoki
    Sasaki, Noriyuki
    Miyayama, Kyoko
    Yokota, Shoko
    Terata, Ryuji
    Gouda, Maki
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (13) : 1291 - 1300
  • [4] Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study
    Ishihara, Hisamitsu
    Yamaguchi, Susumu
    Nakao, Ikko
    Okitsu, Akira
    Asahina, Seitaro
    DIABETES OBESITY & METABOLISM, 2016, 18 (12): : 1207 - 1216
  • [5] Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period
    Reilhac, Caroline
    Dubourg, Julie
    Thang, Carole
    Grouin, Jean-Marie
    Fouqueray, Pascale
    Watada, Hirotaka
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 838 - 848
  • [6] Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period
    Seino, Yutaka
    Sasaki, Takashi
    Fukatsu, Atsushi
    Imazeki, Hisae
    Ochiai, Hidekazu
    Sakai, Soichi
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 981 - 994
  • [7] ELAMIPRETIDE IN PATIENTS WITH BARTH SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL FOLLOWED BY 36-WEEK OPEN-LABEL EXTENSION
    Thompson, Reid
    Manuel, Ryan
    Aiudi, Anthony
    Jones, John J.
    Carr, Jim
    Hornby, Brittany
    Vernon, Hilary
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 957 - 957
  • [8] Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial
    Kadowaki, Takashi
    Inagaki, Nobuya
    Kondo, Kazuoki
    Nishimura, Kenichi
    Kaneko, Genki
    Maruyama, Nobuko
    Nakanishi, Nobuhiro
    Iijima, Hiroaki
    Watanabe, Yumi
    Gouda, Maki
    DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 874 - 882
  • [9] Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)
    Kashiwagi A.
    Shiga T.
    Akiyama N.
    Kazuta K.
    Utsuno A.
    Yoshida S.
    Ueyama E.
    Diabetology International, 2015, 6 (2) : 104 - 116
  • [10] Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial
    Sone, Hirohito
    Kaneko, Tatsuroh
    Shiki, Kosuke
    Tachibana, Yoshifumi
    Pfarr, Egon
    Lee, Jisoo
    Tajima, Naoko
    DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 417 - 426
12345